Histocompatibility Testing and Antibody Detection in Solid Organ Transplantation

hla panels

Histocompatibility Testing

Histocompatibility Testing plays an important role in determining the degree of Human Leukocyte Antigen (MLA) matching between the solid organ recipients and their donors (12). It also includes the donor-recipient Cross-match Testing (XMT) and anti-HLA antibody screening that are crucial examinations in solid organ transplantation, aiming to avoid hyperacute graft rejection and also to predict the immunological outcome of the graft(3.5).

An individual can become sensitized to HLA allo-antigens as a result of blood transfusion, pregnancy or previous organ transplantation. Transplantation of poorly HLA-matched kidneys can result in allosensitization to the mis-matched donor HLA. Approximately 20% of pregnant women produce HLA-specific antibodies to paternally inherited fetal HLA antigens.

Pre transplant risk assessment in solid organ transplantation is important for the selection of the donor to initiate appropriate treatment strategies.


• High immunological risk
• High titre circulating antibodies specific for mismatched donor antigens present at the time of transplantation
• High risk of rejection

• Intermediate immunological risk
• Prior donor reactive sensitization
• Weak sensitization to certain mismatched HLA specificities only

• Low (or standard) immunological risk
• Non-sensitized patients
• Sensitized patients-minimally HLA mismatched organ in absence of known current or historical donor reactive antibodies

risk assessment


antibody screening

solid organ transplantation

sensitized patients

kidney transplantation

pre & post

hla transplant work


1. Claas FHJ, Dankers MK, Oudshoorn M, van Rood JJ, Mulder A, Roelen DL, et al. Differential immunogenicity of HLA mismatches in clinical transplantation.Transpl Immun.

2. Cecka JM. HLA matching for organ transplantation…Why not? Int J Immunogenet.

3. Patel R, Terasaki Pl. Significance of the positive crossmatch in kidney transplantation. N Engl J Med.

4. Billen EV, Christiaans MH, van den Berg-Loonen EM. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.Tissue Antigens.

5. Batal I, Zeevi A, Lunz JG, III, Aggarwal N, Shapiro R, Randhawa P, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med. 2010;34:1534-40.

Download PDF


Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts


Other Related Articles